Market Overview

Lilly Presents Phase II Results for Monoclonal Antibody Ramucirumab in Lung Cancer

Eli Lilly and Company (NYSE: LLY) today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC). Results were presented today during the Lung Cancer – Metastatic Poster Session at the ESMO 2012 Congress (European Society for Medical Oncology), 1:00 p.m. – 2:00 p.m. CET, in Vienna, Austria.

Interim data for a study in chemotherapy-naive patients with advanced NSCLC treated with ramucirumab in combination with first-line ALIMTA® (pemetrexed for injection)/platinum-based chemotherapy (Abstract #1245) and final data for a study in patients treated with ramucirumab in combination with paclitaxel/carboplatinum chemotherapy (Abstract#1287) were presented. The pre-specified interim analysis of progression-free survival (PFS) (Abstract #1245) and final six-month PFS rate (Abstract #1287) support continued development of ramucirumab in lung cancer.

"We are encouraged by these results from two Phase II trials indicating ramucirumab may be beneficial to patients with non-small cell lung cancer," said Richard Gaynor, M.D., vice president, product development and medical affairs for Lilly Oncology. "These findings support our ongoing evaluation of ramucirumab for lung cancer patients and will need to be confirmed in larger pivotal studies."

Abstract # 1245A randomized open-label Phase II study of 140 chemotherapy-naive patients investigated

See full press release

Posted-In: News Guidance Management

 

Most Popular

Related Articles (LLY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional